Kilic Nizamettin, Balkan Emin, Akgoz Semra, Sen Nuri, Dogruyol Hasan
The Medical Faculty of Uludag University, Department of Paediatric Surgery, Bursa, Turkey.
Int J Urol. 2006 Feb;13(2):105-8. doi: 10.1111/j.1442-2042.2006.01240.x.
Treatment with anticholinergic agents is the mainstay of therapy for detrusor instability (DI), a chronic and morbid condition characterized by urge urinary incontinence. The aim of this study is to assess the effectiveness and tolerability of tolterodine and oxybutynin in children with DI.
A total of 60 children with DI were enrolled, 30 (14 male, 16 female, mean age 7.97+/-2.71 years) in the tolterodine group and 30 (12 male, 18 female, mean age 7.33+/-2.23 years) in the oxybutynin group. In this prospective study we reviewed data from 60 children followed for at least 6 months. All of the patients in the study population had a history of dysfunctional voiding. Urodynamic investigations were conducted in all of the patients before and after anticholinergic treatment. Episodes of urge urinary incontinence and adverse events were also evaluated.
Improvements in urge incontinence episodes were similar for the children who received tolterodine or oxybutynin. Improvements in the urodynamic parameters were also the same in the two groups. Adverse events were significantly lower in the tolterodine group (13 events in 13 patients) compared to the oxybutynin group (27 events in 20 patients; P=0.027).
Reductions in urge urinary incontinence episodes were similar with tolterodine and oxybutynin in children with DI. Side-effects were more common with oxybutynin. Treatment of children with DI with tolterodine shows significantly better tolerability and this may enhance children's compliance during long-term treatment.
抗胆碱能药物治疗是逼尿肌不稳定(DI)的主要治疗方法,DI是一种以急迫性尿失禁为特征的慢性疾病。本研究旨在评估托特罗定和奥昔布宁治疗儿童DI的有效性和耐受性。
共纳入60例DI患儿,托特罗定组30例(男14例,女16例,平均年龄7.97±2.71岁),奥昔布宁组30例(男12例,女18例,平均年龄7.33±2.23岁)。在这项前瞻性研究中,我们回顾了60例随访至少6个月的儿童的数据。研究人群中的所有患者均有排尿功能障碍病史。所有患者在抗胆碱能治疗前后均进行了尿动力学检查。还评估了急迫性尿失禁发作情况和不良事件。
接受托特罗定或奥昔布宁治疗的儿童急迫性尿失禁发作的改善情况相似。两组尿动力学参数的改善情况也相同。托特罗定组的不良事件(13例患者出现13次事件)明显低于奥昔布宁组(20例患者出现27次事件;P=0.027)。
托特罗定和奥昔布宁治疗儿童DI时,急迫性尿失禁发作的减少情况相似。奥昔布宁的副作用更常见。用托特罗定治疗儿童DI显示出明显更好的耐受性,这可能会提高儿童在长期治疗中的依从性。